Yescarta
(Axicabtagene ciloleucel)Phase 2Cell therapy
GileadThis medication is used to treat a specific type of blood cancer called non-Hodgkin's lymphoma that has come back or stopped responding to other treatments. It works by using the patient's own immune cells, which are collected and specially modified to recognize and attack cancer cells.[1] Yescarta is currently being investigated across 12 indications[3], with its most advanced program in Phase 2.[1]
Yescarta is one of 280 cell therapy programs targeting Non-Hodgkins Lymphoma. It is currently in Phase 2.
12
Indications
36
Total Trials
19
Active Trials
279
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Yescarta
GileadPhase 2
Velban
EEastern Cooperative Oncology Group
Preclinical
Oncaspar
SServier
Preclinical
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
PEG-Intron
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma18 trials
Show 15 more trials
Axi-cel in CNS Lymphoma
Active, not recruiting·—·Phase 1·NCT04608487·18 enrolled
Follicular Lymphoma3 trials
Diffuse Large B-Cell Lymphoma2 trials
Cell Therapy1 trial
11 more indications
T Cell Therapy1 trial
Encephalopathy1 trial
Long-term Follow-up1 trial
Treatment1 trial
Mantle Cell Lymphoma1 trial
AIDS-Related Diffuse Large B-cell Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Axicabtagene ciloleucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]